Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2014

View Archived Issues

Ignyta reports preliminary data from phase I/II trial of anticancer candidate

Merck KGaA synthesizes new agents that act as SYK inhibitors

Reata studies RTA-408 to treat ocular pain and inflammation following ocular surgery

InterMune reports data from phase III ASCEND trial in idiopathic pulmonary fibrosis

Potential antidiabetic strategy: synergistic effects of GPR40 agonist and DPP IV inhibitor

PMV Pharma and Chiromics form drug discovery collaboration

ImmunoCellular Therapeutics receives orphan drug status in Europe for ICT-107 in glioblastoma

Verastem acquires rights to cancer stem cell inhibitor VS-4718

Myalept obtains FDA approval for rare metabolic disease

FDA accepts filing of peramivir NDA

rEVO Biologics submits IND to FDA for ATryn in preeclampsia

Lilly's once-weekly dulaglutide shows non-inferiority to liraglutide in head-to-head trial

Neuroprotection seen with imatinib in stroke model

Neovacs focuses on four therapeutic areas

New HIV attachment inhibitors designed at Bristol-Myers Squibb

Janssen R&D Ireland patents novel Fabl inhibitors

Synchroneuron begins dosing in phase II study of SNC-102 for tardive dyskinesia

Humanetics and USAMRICD enter into CRADA to study BIO-300 to treat phosgene exposure

Dyax reports results from phase Ia study of DX-2930 for prevention of HAE attacks

Roche synthesizes new modulators of neurogenesis

European approval for Mirvaso for facial erythema of rosacea

RPC-1063 demonstrates favorable safety and PK profiles in healthy subjects

aTyr Pharma completes enrollment in phase I trial of Resokine

Artery Therapeutics presents novel ApoE mimetic peptides with antidiabetic activity

Pierre Fabre researchers prepare new griseofulvin derivatives for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...